Comparative Cost-Effectiveness Analysis of First-Line Immunotherapy for Advanced Melanoma Based on 10-Year Clinical Outcomes
Journal of the National Comprehensive Cancer Network · 2026-09 · 24 (9)
DOI: 10.6004/jnccn.2026.7031 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2026-09. Verfasst von Guiyuan Xiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Melanoma, Immunotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Background
Recently, the CheckMate 067, KEYNOTE-006, and RELATIVITY-047 trials demonstrated the long-term efficacy and safety of 5 first-line therapies for advanced melanoma, including nivolumab + relatlimab, with >10 years of follow-up. However, the long-term economic outcomes are still unclear. This study aimed to assess the comparative cost-effectiveness of these strategies from a US health care perspective using more than a decade of clinical trial data.
Methods
Based on the data from clinical trial reports, we simulated a cohort of 1,662 patients with advanced melanoma across 5 treatment groups in which patients received ipilimumab, nivolumab, pembrolizumab, nivolumab + ipilimumab, or nivolumab + relatlimab as first-line therapy. A flexible parametric survival model was used, combined with background mortality rates, to estimate patients’ lifetime overall survival and progression-free survival. A partitioned survival model was constructed to assess the total cost, quality-adjusted life-years (QALYs), total life-years, and incremental cost-effectiveness ratios (ICERs) for the 5 treatment strategies. Sensitivity analyses, including univariate, probabilistic, scenario, and subgroup analyses, were conducted to evaluate the robustness of the model and population differences.
Results
Nivolumab + ipilimumab provided the highest QALYs (7.30), followed by nivolumab + relatlimab (6.67 QALYs). Ipilimumab and nivolumab + relatlimab were associated with the lowest ($239,168) and highest ($471,610) costs, respectively. Compared with nivolumab, only nivolumab + ipilimumab resulted in ICERs below the willingness-to-pay threshold of $150,000/QALY. Drug costs and body weight were the most influential factors affecting ICERs. Nivolumab + ipilimumab demonstrated the highest probability of being the most cost-effective strategy.
Conclusions
Among first-line immunotherapy strategies for advanced melanoma, nivolumab + ipilimumab and nivolumab + relatlimab provided the greatest survival benefits. After integrating treatment costs, safety, and health-related quality of life, nivolumab + ipilimumab was the most cost-effective strategy under base-case assumptions, followed by nivolumab monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China.
- 2Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA.
Zitieren
APA
Xiang, G., Sun, Y., Yang, X., & Liu, Y. (2026). Comparative Cost-Effectiveness Analysis of First-Line Immunotherapy for Advanced Melanoma Based on 10-Year Clinical Outcomes. Journal of the National Comprehensive Cancer Network, 24(9). https://doi.org/10.6004/jnccn.2026.7031
Vancouver
Xiang G, Sun Y, Yang X, Liu Y. Comparative Cost-Effectiveness Analysis of First-Line Immunotherapy for Advanced Melanoma Based on 10-Year Clinical Outcomes. Journal of the National Comprehensive Cancer Network. 2026;24(9). doi:10.6004/jnccn.2026.7031
BibTeX
@article{Xiang2026,
author = {Xiang, Guiyuan and Sun, Yin and Yang, Xue and Liu, Yao},
title = {Comparative Cost-Effectiveness Analysis of First-Line Immunotherapy for Advanced Melanoma Based on 10-Year Clinical Outcomes},
journal = {Journal of the National Comprehensive Cancer Network},
year = {2026},
volume = {24},
number = {9},
doi = {10.6004/jnccn.2026.7031}
}
EUVIMED